A new “smart drug” has shown promise for women with metastatic triple-negative breast cancer, based on data from a clinical trial published in the New England Journal of Medicine.
“I think this drug has the potential to change practice, because the data looks so compelling, even with the relatively small number of patients in the trial,” said Kevin Kalinsky, MD, MS, assistant professor of medicine at Columbia University Vagelos College of Physicians and Surgeons and the paper’s senior author.
“There’s an unmet need for patients with metastatic triple-negative breast cancer, and we see significant tumour shrinkage with this new therapy,” Kalinsky added.
Triple-negative breast cancer is an aggressive disease and is more common, relative to other breast cancers, in young women and African-American women.
Triple-negative breast cancers do not express the estrogen receptor, progesterone receptor, or HER2.
Thus, historically, treatments only included chemotherapy for triple-negative breast cancer and not targeted therapy, such as hormone therapy or Herceptin.
The drug, sacituzumab govitecan, is part of an emerging class of “smart drugs” designed to deliver a toxic payload directly to tumour cells.
The drug is a fusion of an antibody that recognises a protein expressed by breast cancer cells known as trop2 and the metabolite of an established chemotherapy drug (irinotecan), SN-38.
The antibody delivers SN-38 directly to the cancer cell.
Kalinsky said: “With this smart drug, we can deliver a much higher dose of the payload since we’re sending it directly to the cancer cells.”
The trial tested the drug in 108 women with metastatic triple-negative breast cancer who had already been through two or more previous treatment regimens.
By the time a patient has started her third or fourth treatment regimen, the chance of a response is low.
Sacituzumab govitecan, however, produced a better response rate in pre-treated patients than what has been historically seen with other standard therapies.
Overall, 33 percent of patients responded to the drug – the median duration of response was 7.7 months, and median overall survival was 13 months.
“We saw significant tumour shrinkage with the drug, and it took longer for the cancer to progress compared to other drugs commonly used to treat metastatic triple-negative breast cancer,” Kalinsky said.
Nine long-term responders remained free of disease progression for over a year.
“Having smaller tumours can be incredibly meaningful to a patient’s quality of life,” Kalinsky added. “When tumours shrink, patients are more likely to experience improvement in symptoms, like pain.”
The main side effects seen in the trial were hair loss, diarrhoea, and fatigue, but only 3 percent of patients had to stop taking the drug due to adverse events.
“Importantly, the drug did not cause neuropathy, the numbness and tingling that can be quite painful and limiting for patients,” Kalinsky mentioned. “Neuropathy can make it difficult to dress oneself, or even walk. It is promising to have an active treatment that does not have neuropathy as a side effect.”
The drug is also being tested in other types of breast cancer, bladder cancer, and prostate cancer.
“We are excited to have participated in the early development of this novel drug, which we hope will change the treatment paradigm for patients with metastatic triple-negative breast cancer,” said Gary Schwartz, MD, chief of hematology/oncology at New York-Presbyterian/Columbia University Irving Medical Center and deputy director of New York-Presbyterian/Columbia’s Herbert Irving Comprehensive Cancer Center.